Menopause in Women with Sickle Cell Disease

Monica Adedeji,Elizabeth Andrews,Gaye Riddick-Burden,Sanaa Rizk

DOI: https://doi.org/10.1093/jscdis/yoae002.052

2024-06-01

Abstract:Abstract Presentation Date: 6/8/2024 Presentation Start Time: 6:00 PM Background Sickle cell disease (SCD) is the most common genetic disorder globally. With improved SCD management over the decades, more focus has been directed on long-term survival, and age-related complications. While menarche has been studied in adolescents with SCD and seems to be delayed, since women with SCD previously did not live long enough to experience menopause, there remains a paucity of data on menopause so far. This study sought to illicit the menopause experience in women with SCD including the age of onset and symptom severity. We hypothesized that women with SCD may have earlier onset menopause compared to women without SCD as reports have mentioned ovarian sickling as a proposed mechanism of premature ovarian failure, and iron overload as a possible cause of endocrinopathy--leading to impaired ovarian reserve. Methods Within the Jefferson Health Network, 37 menopausal Black women with SCD were interviewed using a standardized questionnaire inquiring about their menopause experience. Mean, median and standard deviation were calculated using basic statistics. Results Women with SCD, irrespective of genotype, underwent menopause at a median age of 48 years compared to 52 years--the national median age of menopause in Black women. Furthermore, women not on hydroxyurea had an increased incidence of menopausal symptoms including weight gain, hot flashes, sleep disturbances, vaginal dryness and mood swings, compared to women taking hydroxyurea. Conclusions While this study’s results are limited due to small sample size, it sheds light on the menopause experience in women with SCD and further highlights the need for further research on this topic. Clinical Data of Menopause in Women with Sickle cell disease (SCD) With and Without Hydrea Therapy